A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with -Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Full Text
European Urology, 04/23/2012
Evidence Based Medicine
Gacci M et al. – The meta–analysis of the available cross–sectional data suggests that phosphodiesterase type 5 inhibitors (PDE5–Is) can significantly improve lower urinary tract symptoms (LUTS) and erectile function in men with benign prostatic hyperplasia (BPH). PDE5–Is seem to be a promising treatment option for patients with LUTS secondary to BPH with or without erectile dysfunction.